BiomX reports Q4 2022 net loss $28.3M; BX004 Part 1 shows >90% bacterial reduction

BiomX Inc.

Cash, short-term deposits, restricted cash $34.3M at Dec 31, 2022; cash runway through at least mid-2024.
Net loss for 2022 was $28.3M vs $36.2M in 2021; R&D expenses $16.2M, down from $22.7M.
BX004 Phase 1b/2a Part 1: mean P. aeruginosa reduction of 1.42 log10 CFU/g vs placebo 0.28; no safety events.
Part 2 dosing initiated; results expected Q3 2023; CF Foundation to invest $2M second tranche.
Raised $7.5M private placement in Feb 2023; $6M contingent on shareholder approval; OrbiMed and CF Foundation participated.

item 2.02 item 5.08 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BiomX Inc. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 29, 2023, BiomX Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-023846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.